MDS 2026 — PD Genetic and Molecular Mechanisms

MDS 2026 — Parkinson's Disease Genetic and Molecular Mechanisms

Congress: Movement Disorder Society (MDS) International Congress 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Dates: October 4-8, 2026

This page synthesizes the latest research on Parkinson's disease genetics and molecular mechanisms presented at MDS 2026, with emphasis on key genetic risk factors, molecular pathways, and therapeutic implications.

Overview

MDS 2026 showcased significant advances in understanding the genetic architecture of Parkinson's disease and the molecular mechanisms underlying neurodegeneration. Key themes included:

• LRRK2 biology: Kinase inhibitors advancing to late-stage trials
• GBA-associated PD: Recognition as a distinct clinical subtype
• Alpha-synuclein biology: Seed amplification assays reaching clinical validation
• Emerging genetic risk factors: New loci identified through multi-ethnic GWAS
• Polygenic risk scores: Moving toward clinical implementation

1. LRRK2 Pathway and Therapeutic Targeting

Genetic Basis

[LRRK2](/genes/lrrk2) (Leucine-Rich Repeat Kinase 2) is the most common monogenic cause of Parkinson's disease[@cookson2023]. Pathogenic variants include:

| Variant | Domain | Effect | Population Prevalence |
|---------|--------|--------|----------------------|
| G2019S | Kinase | ↑ Kinase activity 2-3x | ~5% familial, ~1% sporadic PD |
| R1441C/G/H | ROC | ↓ GTPase activity | Basque, worldwide |
| I2020T | Kinase | ↑ Kinase activity | Japanese families |

Molecular Mechanisms

MDS 2026 — Parkinson's Disease Genetic and Molecular Mechanisms

Congress: Movement Disorder Society (MDS) International Congress 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Dates: October 4-8, 2026

This page synthesizes the latest research on Parkinson's disease genetics and molecular mechanisms presented at MDS 2026, with emphasis on key genetic risk factors, molecular pathways, and therapeutic implications.

Overview

MDS 2026 showcased significant advances in understanding the genetic architecture of Parkinson's disease and the molecular mechanisms underlying neurodegeneration. Key themes included:

• LRRK2 biology: Kinase inhibitors advancing to late-stage trials
• GBA-associated PD: Recognition as a distinct clinical subtype
• Alpha-synuclein biology: Seed amplification assays reaching clinical validation
• Emerging genetic risk factors: New loci identified through multi-ethnic GWAS
• Polygenic risk scores: Moving toward clinical implementation

1. LRRK2 Pathway and Therapeutic Targeting

Genetic Basis

[LRRK2](/genes/lrrk2) (Leucine-Rich Repeat Kinase 2) is the most common monogenic cause of Parkinson's disease[@cookson2023]. Pathogenic variants include:

| Variant | Domain | Effect | Population Prevalence |
|---------|--------|--------|----------------------|
| G2019S | Kinase | ↑ Kinase activity 2-3x | ~5% familial, ~1% sporadic PD |
| R1441C/G/H | ROC | ↓ GTPase activity | Basque, worldwide |
| I2020T | Kinase | ↑ Kinase activity | Japanese families |

Molecular Mechanisms

LRRK2 participates in multiple cellular pathways relevant to PD pathogenesis:

LRRK2 Kinase Inhibitors in Development

Multiple LRRK2 inhibitors have advanced through clinical development:

| Drug | Company | Mechanism | Stage |
|------|---------|-----------|-------|
| DNL151/DNL312 | Denali/Biogen | ATP-competitive | Phase 2/3 |
| BIIB122 | Biogen | ATP-competitive | Phase 2b |
| PF-06649751 | Pfizer | ATP-competitive | Phase 1 |

Key challenges addressed at MDS 2026:

• Blood-brain barrier penetration optimization
• Peripheral toxicity mitigation (kidney, lung)
• Patient selection through genetic testing
• Biomarker development for target engagement

LRRK2 Gene Therapy Approaches

Novel therapeutic modalities include:

• Antisense oligonucleotides (ASOs): Reduce LRRK2 expression
• RNAi approaches: Viral-delivered shRNA targeting mutant alleles
• CRISPR-based editing: Mutation-specific correction strategies

2. GBA-Associated Parkinson's Disease

Genetic Background

[Glucocerebrosidase (GBA1)](/genes/gba) variants are the most significant genetic risk factor for sporadic PD, with 5-10% of PD patients carrying pathogenic variants[@gba2024].

Clinical Characteristics

GBA-PD represents a distinct clinical subtype:

• Earlier age at onset: Mean 5-10 years earlier
• Faster cognitive decline: Higher risk of PD dementia
• Earlier autonomic dysfunction: Orthostatic hypotension, GI symptoms
• Distinct sleep architecture: RBD may precede motor symptoms
• Higher non-motor symptom burden: Anxiety, depression, anosmia

Molecular Mechanisms

| Pathway | Dysfunction | Therapeutic Target |
|---------|-------------|-------------------|
| Lysosomal function | ↓ GCase activity | Enzyme enhancement |
| Alpha-synuclein clearance | ↑ Aggregation | Ambroxol, substrate reduction |
| Lipid metabolism | ↑ Glucosylceramide | Substrate reduction therapy |
| Autophagy | Impaired clearance | Autophagy inducers |

Therapeutic Approaches

See [GBA Pathway in PD](/mechanisms/gba-pathway-parkinsons) for detailed coverage.

3. Alpha-Synuclein Biology

SNCA Gene Variants

[SNCA](/genes/snca) encodes alpha-synuclein, the key protein in Lewy body pathology:

| Variant | Effect | Phenotype |
|---------|--------|-----------|
| A53T (SNCAm) | Early onset | Rapid progression, autonomic dysfunction |
| A30P | Incomplete penetrance | Variable |
| Triplication | Gene dose effect | Early onset, severe dementia |
| Duplication | Gene dose effect | Typical PD presentation |

Seed Amplification Assays (SAAs)

MDS 2026 featured updates on clinical validation of alpha-synuclein SAAs:

| Assay | Sensitivity | Specificity | Sample |
|-------|-------------|-------------|--------|
| RT-QuIC (CSF) | 87-95% | 90-95% | CSF |
| PMCA (CSF) | 88-96% | 92-98% | CSF |
| SynuLight (blood) | 80-85% | 85-90% | Blood |

Key applications:

• Differential diagnosis of synucleinopathies
• Pre-motor detection in at-risk populations
• Disease progression monitoring
• Clinical trial enrichment

Molecular Mechanisms of Aggregation

See [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) for detailed mechanisms.

4. PARK Genes and Monogenic PD

Autosomal Recessive Forms

| Gene | PARK Number | Protein Function | Phenotype |
|------|-------------|-----------------|-----------|
| [PRKN](/genes/parkin) (PARK2) | PARK2 | E3 ubiquitin ligase | Early onset, dystonia |
| [PINK1](/genes/pink1) (PARK6) | PARK6 | Mitochondrial kinase | Early onset |
| [DJ-1](/genes/park7) (PARK7) | PARK7 | Oxidative stress response | Early onset |
| [ATP13A2](/genes/atp13a2) (PARK9) | PARK9 | Lysosomal ATPase | Juvenile parkinsonism, dementia |

Autosomal Dominant Forms

| Gene | PARK Number | Protein Function | Phenotype |
|------|-------------|-----------------|-----------|
| [SNCA](/genes/snca) (PARK1/4) | PARK1/4 | Synaptic protein | Early onset, dementia |
| [LRRK2](/genes/lrrk2) (PARK8) | PARK8 | Kinase/GTPase | Typical PD |
| [VPS35](/genes/vps35) (PARK17) | PARK17 | Retromer component | Late onset, good levodopa response |

Emerging Genes

Recent discoveries include:

• DNAJC13: Endosomal trafficking
• CHCHD2: Mitochondrial function
• RIC3: Acetylcholine receptor assembly
• VPS13C: Mitochondrial quality control

5. Emerging Genetic Risk Factors

Multi-Ethnic GWAS Findings

Large-scale GWAS have identified >90 PD risk loci. Key findings from recent multi-ethnic studies:

| Population | Novel Loci | Notable Genes |
|------------|------------|---------------|
| European | 78 loci | LRRK2, GBA, SNCA |
| East Asian | 15 loci | FAM47E, SCARB2 |
| African | Novel variants | Population-specific |
| Latino | 8 loci | GCH1, MIR4697 |

Polygenic Risk Scores

Clinical implementation of PRS is advancing:

• Risk stratification: Identifying high-risk individuals
• Age at onset prediction: Modest predictive value
• Progression modeling: Correlates with clinical outcomes
• Therapeutic response: May predict levodopa response

Gene-Environment Interactions

MDS 2026 highlighted gene-environment interplay:

• LRRK2 + pesticide exposure: Synergistic risk
• GBA + smoking: Modifies risk
• PRKN + traumatic brain injury: Increased vulnerability

6. Molecular Mechanisms Integration

Pathway Cross-Talk

Convergence on Common Pathways

7. Therapeutic Implications

Precision Medicine Approaches

| Genetic Subtype | Therapeutic Strategy | Development Stage |
|-----------------|-------------------|------------------|
| LRRK2 G2019S | Kinase inhibitors | Phase 2/3 |
| GBA1 | Enzyme enhancement | Phase 2 |
| SNCA | Immunotherapy | Phase 2/3 |
| PRKN/PINK1 | Mitophagy activators | Preclinical |
| ATP13A2 | Lysosomal function | Preclinical |

Biomarker Development

• Genetic testing: Clinical implementation
• Fluid biomarkers: α-syn SAAs, NFL, p-tau
• Imaging biomarkers: Tau PET, dopamine imaging
• Digital biomarkers: Wearable movement analysis

8. Clinical Implementation

Genetic Testing Recommendations

Tier 1 (all PD patients):

• GBA sequencing
• LRRK2 G2019S (population-specific)
• SNCA analysis

• PRKN, PINK1, DJ-1
• [VPS35](/genes/vps35)
• [ATP13A2](/genes/atp13a2)

Genetic Counseling

Key considerations:

• Pre-test counseling
• Variant interpretation
• Cascade testing options
• Reproductive implications

9. Related Pages

• [LRRK2 Gene](/genes/lrrk2)
• [GBA Gene](/genes/gba)
• [SNCA Gene](/genes/snca)
• [Alpha-Synuclein Protein](/proteins/alpha-synuclein)
• [LRRK2 Pathway in PD](/mechanisms/pd-lrrk2-pathway)
• [GBA Pathway in PD](/mechanisms/gba-pathway-parkinsons)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [MDS 2026 — Genetics and Biomarkers](/biomarkers/mds-2026-genetics-biomarkers-movement-disorders)
• [Multi-Ethnic PD GWAS](/mechanisms/multi-ethnic-pd-gwas)

10. References

References

alessi2018, LRRK2 kinase in Parkinson's disease (2018)
cookson2023, The role of LRRK2 in Parkinson's disease (2023)
gba2024 (2024)
mds2026, MDS Congress 2026 (2026) [1](https://www.mdscongress.org)
tolosa2022, LRRK2 in Parkinson disease: Challenges of clinical trials (2022)